DOI: https://doi.org/10.22141/2224-0713.5.91.2017.110857

Dopamine receptor agonists in comprehensive pathogenetic therapy of Parkinson’s disease

I.M. Karaban, N.V. Karasevych

Abstract


The article considers in detail the pathogenetic factors of Parkinson’s disease development. The attention was paid to the treatment issues given the role of dopamine. The characteristics of the dopamine receptor agonist group, in particular, pramipexole, are given.

Keywords


Parkinson’s disease; dopamine; dopamine receptor agonists

References


Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group // JAMA. —

, Oct 18. — 284(15). — 1931-8.

Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression // JAMA. —

— 287(13). — 1653-61.

Литвиненко И.В. и соавт. Боль и депрессия при болезни Паркинсона: новые терапевтические возможности прамипексола // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2008. — 11. — С. 36-38.

Summary of the recomendations of the EFNS/MDS-ES review on the therapeutic management of Parkinson’s disease / Ed. by J. Ferreira, R. Katzenschlager, B. Bloem et al. // European Journal of Neurology. — 2013. — Vol. 20. — 5-15.

Aiken C.B. Pramipexole in psychiatry: a systemic review of the liter-ature // J. Clin. Psychiat. — 2007. — 68. — 1230-1236.

Corrigan M.H., Denahan A.Q. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression // Depress Anxiety. — 2000. — 11(2). — 58-65.

Barone P., Scarzella R., Marconi A., Antonini L., Morgante F., Bracco M., Zappia B. Musch and the Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease // Journal of Neurology. — 2006. — 253(5). — Р. 601-607.

Albert F.G. Leentjens, Jurgen Koester, Barbara Fruh et al. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies // Clinical Therapeutics. — 2009. — № 1.




Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта